1	"People here live in denial": A qualitative study of the pervasive impact of
2	stigma on asthma diagnosis and care in Kenya and Sudan
3	
4	Rana Ahmed <sup>1¶</sup> , Stephen Mulupi <sup>2¶</sup> , Miriam Taegtmeyer <sup>3</sup> , Jane Ardrey <sup>4</sup> , Graham Devereux <sup>3</sup> ,
5	Martha Chinouya <sup>5</sup> , Rashid Osman <sup>1</sup> , ElHafiz Hussein <sup>1</sup> , Sundos Modawey <sup>1</sup> , Hoyam Eltahir <sup>1</sup> ,
6	Caroline Kinyua <sup>2</sup> , Helen Meme <sup>2</sup> , Elizabeth H Shayo <sup>6</sup> , Asma El Sony <sup>1</sup> , Rachel Tolhurst <sup>4</sup> *
7	
8	<sup>1</sup> Department of Lung Health, The Epidemiological Laboratory, Khartoum, Sudan
9	<sup>2</sup> Kenya Medical Research Institute- Centre for Respiratory Diseases Research, Nairobi,
10	Kenya
11	<sup>3</sup> Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place,
12	Liverpool, UK L35QA
13	<sup>4</sup> Department of International Public Health, Liverpool School of Tropical Medicine,
14	Pembroke Place, Liverpool, UK L35QA
15	<sup>5</sup> Faculty of Education, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool
16	L3 5QA
17	<sup>6</sup> National Institute for Medical Research, P.O Box 9653,11101 Barack Obama Drive, Dar Es
18	Salaam Tanzania
19	
20	
21	
22	Corresponding author: Rachel Tolhurst
23	Rachel.Tolhurst@lstmed.ac.uk
24	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. ¶ Joint first authors

# 25 Abstract

Epidemiological studies show a global increase in asthma, straining healthcare systems in low- and middle-income countries. There are multiple barriers to accessing diagnosis and treatment in Sub-Saharan African countries like Kenya and Sudan such as healthcare infrastructure, diagnostic tools, healthcare workers' capacities, and cost. Asthma can be well controlled using safe and cost-effective treatments such as inhalers. Stigma related to asthma negatively impacts treatment-seeking and adherence in higher-income settings, with limited information about such impacts in Sub-Saharan Africa.

We conducted qualitative interviews and Focus Group Discussions in Kenya and Sudan to explore health systems aspects of diagnosis and management of chronic respiratory diseases. Participants included patients, primary care healthcare workers, hospitals, and community actors. Data were analysed through a framework approach; our initial analysis showed that asthma stigma was prevalent in both countries. Further analysis was done through Health, Stigma, and Discrimination Framework by Stangl.

Negative perceptions about the aetiology and prognosis of asthma contribute to stigma. Anticipated, internalized stigma, and enacted stigma affects individuals with asthma, encouraging them to hide their symptoms and resist diagnosis. This contribute to delayed healthcare seeking and treatment uptake, impacting both individuals with asthma and health professionals. Overall, stigma exacerbates challenges in communicating diagnosis, managing the illness, and maintaining psychosocial health and well-being for those with asthma.

45 Poor asthma control can exacerbate fear and stigma. Improving asthma control has the potential 46 to reduce fear and positively influence community norms. The rollout of inhalers and spacers 47 for asthma treatment should be accompanied by deliberate stigma reduction strategies and 48 awareness raising at all levels of the system.

# 49 Introduction

### 50 Asthma care

51 The noncommunicable lung disease asthma is the most common chronic disease of 52 childhood, it is characterised by variable airflow obstruction[1]. Symptoms include, wheeze, 53 cough, breathlessness, and acute deteriorations in symptoms (exacerbations) requiring input 54 from health services for treatment. Although asthma has an inherited component[2], there is no 55 family history in 50% of cases and environmental exposures are important in aetiology. In sub-56 Saharan Africa (SSA)[3] the prevalence of asthma is 9-20%[4]. Prevalence has increased in 57 recent decades[5] with the highest prevalence of severe asthma in African children[6,7]. 58 Childhood asthma is 'underdiagnosed and undertreated' in low-and-middle-income countries 59 (LMICs).[8] resulting in high mortality and morbidity burden that includes adverse 60 developmental outcomes, school absence, reduced academic achievement and social 61 opportunities and (as adults) disadvantages in employment and livelihoods. Poorly controlled 62 asthma is also a cause of catastrophic healthcare expenditure, exposing whole households to 63 risk of impoverishment [9].

64 Asthma diagnosis and managment remains challenging in sub-Saharan African (SSA). Diagnosis is based on clinical evaluation of symptoms and a therapeutic trial of treatment [10]. 65 66 When available a clinical diagnosis may be supported by tests such as spirometry, peak flow 67 monitoring, and exhaled nitric oxide measurement. Asthma diagnosis is difficult in SSA 68 contexts where primary care is poorly resourced, healthcare workers lack training in asthma 69 diagnosis and systems are not designed for chronic disease management[11]. There is no cure 70 for asthma; treatment aims to control symptoms and reduce exacerbations. Typical asthma treatment comprises a combination of 'preventer' and 'reliever' therapies, most effectively 71 72 administered by inhaler via a spacer device if a metered dose inhaler is used. These treatments

are of proven efficacy, safe and highly cost-effective, reducing the incidence of acute
exacerbations by 70% and making asthma deaths largely preventable[12]. Although these
inhalers are on the WHO essential medicines list, spacers are not.

76 To date, efforts to address gaps in asthma care in SSA have focused on improving 'supply side' 77 factors such as policy/guideline documents, training healthcare workers and improving access 78 to peak flow meters, and inhaled treatments. For example, Epilab (a local health non-79 governmental organisation in Sudan) introduced an asthma standard case management 80 programme to Gezira district hospitals, which saw a significant reduction in hospital, and 81 emergency-room admissions[13]. Unfortunately, this is the exception rather than the rule, as 82 most initiatives to improve availability and affordability have been unsuccessful.[14,15] 83 Notably; the provision of low-cost inhalers by the Asthma Drug Facility failed because of a 84 lack of demand, despite a high burden of asthma and drastic reductions in asthma-related 85 emergencies among those who did use provided inhalers.[14] Most interventions have failed to address 'demand side' factors (, socio-economic context, perceptions and behaviours of 86 87 individuals, households and communities), important in determining how and when health 88 services are accessed. Uptake may continue to be poor when the perceived risks to the 89 individual outweigh the benefit of health seeking.

### 90 Stigma

Stigma is increasingly recognised as an important determinant of asthma control in the global north[16–20] where it is associated with delayed diagnosis, reluctance to use inhalers and reduced quality of life[21]. However, little is known about asthma stigma in SSA. In Tanzania, children fear eating and playing with children with asthma[22]; in Sudan widespread asthma stigma particularly affects young women, impacting marriage prospects and quality of life[22,23]. A Ugandan study revealed respiratory symptoms are stigmatised because of their

97 link with TB and with asthma thought to be contagious, and adults try to keep their wheezing 98 child secret[24]. In Kenya, only 33% of parents of children with asthma accepted the diagnosis, 99 34% feared inhalers and only 31% felt that long term therapy was necessary[25]. While 100 addressing knowledge gaps is important [26], a deeper understanding of how stigma 101 undermines asthma care is needed in the context of SSA.

102 Stigma is a contested concept, influentially defined by Goffman as an "attribute that is deeply 103 discrediting" and that reduces the bearer "from a whole and usual person to a tainted, 104 discounted one" [27]. Jones et al. (1984)[28], use Goffman's (1963, p.4)[27]observation that 105 stigma can be seen as a relationship between an "attribute and a stereotype" to produce a 106 definition of stigma as a "mark" (attribute), linking a person to undesirable characteristics (or 107 stereotypes). This focus on stigmatised individuals has been critiqued, in favour of 108 understanding stigma as a process occurring through social and structural forces across 109 multiple socio-ecological levels [29–31]. These later conceptualisations emphasise stigma in 110 the context of social determinants of health, such as poverty and social stratification [32,33].

111 Arguing against constructions of stigma focused on specific diseases. Stangl et al (2019) 112 propose a framework drawn from stigmatised health conditions (including HIV, mental health, 113 and obesity) to inform research, intervention development, and policy on health-related 114 stigmas, which we apply in this paper. They identify four key domains of the stigma process, which ultimately create health and social impacts. First, drivers and facilitators of stigma: 115 116 drivers are inherently negative, including fear of infection, social judgement or blame, whilst 117 facilitators may either minimise or exacerbate stigma. Second, 'stigma marking' refers to the 118 application of stigma to an individual; similarly, Link and Phelan refer to placing a 'label' on 119 a person, which links them to undesirable characteristics [29]. Stangl *et al* emphasise labelling 120 is further shaped by gender, race, occupation, ethnicity, kinship. Third, marking leads to stigma 121 experiences (that is lived realities) and practices (beliefs, attitudes and actions of others towards

122 a stigmatised person). A distinction is made here between: 'self-stigma' (sometimes referred 123 to as 'internalised stigma'), which refers to "a stigmatised group member's own adoption of negative societal beliefs and feelings, as well as the social devaluation associated with their 124 125 stigmatised status''[34, pg. 614; 35]; perceived stigma (i.e. perceptions about how stigmatised groups are treated in a given context); and anticipated stigma (i.e. expectations of bias being 126 127 perpetrated by others). Scrambler (1998)[36] makes an additional distinction between 'anticipated' stigma and the 'enacted stigma' of overt acts of social exclusion. Finally, stigma 128 129 manifestations lead to a range of outcomes for affected populations (including access to and 130 uptake of healthcare) and relevant institutions (including health services).

131 We present findings from two linked studies (one in Sudan and one in Kenya) investigating 132 health system readiness to respond to people with symptoms of chronic respiratory disease 133 (CRDs), including asthma. Although not primarily designed to study the impact of asthma 134 stigma, it emerged as such a strong theme in both countries and across all participant types that 135 we feel obliged to report these findings separately in the hope they can assist programmes 136 responding to the increasing need for asthma care in SSA. This paper adds to the evidence 137 generated in earlier studies in Kenya, Sudan and Tanzania, highlighting policy and health carelevel impediments to effective diagnosis and management of asthma in East African healthcare 138 facilities[37; 43]. 139

# 140 Materials and methods

## 141 IMPALA (parent study) overview and sub-study designs

We conducted two linked studies within the NIHR-funded International Multidisciplinary Program to Address Lung Disease and Tuberculosis in Africa (IMPALA)[38] an 11-country consortium aiming to improve the health of children and adults in Africa through multi-disciplinary applied health research on lung health and TB. The first

146 study, in Sudan, used an action research design. An initial health systems analysis and 147 qualitative methods engaged actors from within healthcare facilities and community subsystems to collate experiences, identify requirements and generate context-specific 148 149 interventions to integrate chronic lung disease services into existing health systems. The second study, in Kenya, investigated public healthcare facilities' readiness to respond to people 150 151 presenting with symptoms of chronic respiratory diseases, within the context of a devolved county government system. Both studies explored community members' perceptions of 152 153 chronic respiratory diseases, asthma and care seeking experiences, the roles of community 154 actors (including community health volunteers (CHVs) in Kenya) in supporting referrals to 155 healthcare facilities, and healthcare workers' experiences in diagnosing, treatment and 156 subsequent management of asthma.

## 157 Settings

158 In Sudan, the study was based on eight purposively selected health facilities and their 159 catchment communities in two localities within Gezira State. We selected Gezira State, because 160 there is an asthma management program at district level hospitals where the Comprehensive 161 Approach to improve quality of Lung Health Services (CLHS) has been implemented by 162 EpiLab, [13,39], a local health research and development NGO with a mission to create and 163 maintain access to effective health services. We purposively selected health facilities to 164 represent experiences from district and health centre level facilities, in urban and rural 165 locations, including those with and without support from Epilab. Four health facilities with Epilab support had an emergency room with nebulizers, and oxygen supply/canisters, an 166 167 asthma clinic with a peak flow meter, a medical officer, a nurse and clerk or medical assistant 168 for recording and reporting, while others only had emergency rooms with nebulizers, and 169 oxygen supply/canisters.

170 In Kenya, the study was conducted in Meru County, central Kenya. We purposively selected four rural public healthcare facilities - two health centres, two primary referral hospitals, 171 distributed across two of the nine sub-counties within Meru County. The fifth facility, Meru 172 173 Teaching and Referral Hospital, was selected as it is a regional tertiary hospital and we wanted to explore referral pathways. All the health facilities provided diagnostic and treatment 174 175 services, for asthma. None of the public facilities provided spirometry services, although peak 176 flow meters were mentioned as available at hospital level. Similarly, only hospitals had medical 177 officers.

178

### 179 Selection and recruitment of participants

180 Study participants in both contexts were selected purposively, for their roles as 181 (potential) users and consumers of healthcare services from the local healthcare facilities 182 (community members and patients); or support in the provision of healthcare services 183 (community health volunteers and facility healthcare workers). All participants were adults 184 (over 18) and provided written informed consent (Table 1).

185 <b>Tal</b>	ole 1: Compa	arison of	participant	selection	and recruitment
----------------	--------------	-----------	-------------	-----------	-----------------

Study participants	Sudan	Kenya
Primary care and	Purposively selected to include	Purposively selected based on their
hospital clinicians	different types of clinical role	roles in providing care to patients with
	(General practitioners, medical	symptoms of chronic respiratory
	director and medical assistants)	diseases, and included clinical officers,
	who had a wide range of years of	medical doctors, medical social
	experience in clinical work and	workers.
	administration	
Community actors	Purposively selected from the	All Community Health Volunteers
	general community in areas served	(CHVs) supporting eight Community
	by the selected health facilities to	Health Units (CHU) linked to the
	reflect a range of literacy levels,	primary health facilities and hospitals.
	socio-economic backgrounds,	
	distance (near or further) from the	
	health facilities, and experiences	
	of living with, or being affected by	
	asthma.	
Male and female	Purposively selected to represent	Selected through convenient sampling,
asthma patients*	all asthma severities and	based on attendance at study site
	catchment communities at varied	during the study period with asthma
	distances from the health facility;	confirmed clinically during same day
	identified by the field team and	consultation (including new and
	health workers from the Asthma	former diagnosis)
	Standard Case Management	
	Programme at study sites.	

186 \* Clinically confirmed asthma

### 187 Data collection

Data were collected between August 2019 and November 2020 (Kenya), and February to August (2019) in Sudan. All interviews and focus group discussions (FGDs) were conducted by research assistants trained in qualitative research methods. FGDs were conducted in the community at venues preferred by the participants. Health workers' interviews were conducted within the health facility premises.

193 In Kenya, interviews were led by a single investigator (SM) and four research assistants who

194 also took field notes on key issues of discussion. Interviews involving healthcare workers were

195 carried out in English, whilst interviews with CHVs and community members were conducted

in Swahili. In Sudan, all interviews were conducted in Arabic and led by four co-investigatorsand five research assistants.

Health worker interviews: Health workers' interviews in both contexts were guided by semistructured topic guides (see supplementary materials) exploring health workers' perceptions of
health facility readiness for integration of CRD management, with a focus on asthma;
perceptions, expectations and threats for anticipated integration of CRDs.

202 Community Focus Group Discussions (FGDs):

In Sudan, community FGDs were organised by gender and age (younger (18-39 years) and older ( $\geq$ 40 years)) in line with the social structure and norms of the Sudan local society. A separate focus group of young women (18-39) was also conducted after the observation that asthma is a highly stigmatising illness in this group in Sudanese society. FGDs explored community understanding of CRDs especially asthma, community care-seeking practices for CRDs, community experiences with and priorities for care, including risks and economic impacts encountered.

210 In Kenya, we conducted focus group discussions with CHVs supporting eight Community 211 Health Units (CHUs) that were linked to the primary health facilities and hospitals. In each 212 CHU, FGDs were stratified by gender and consisted of 6-8 participants. Topic guides for CHVs 213 examined their understanding of asthma, roles and experiences in providing care (including 214 supporting referrals of community members to healthcare facilities for CHVs), and perceptions 215 of stigma for asthma in the community. Additionally, FGDs were conducted with community 216 members living within the catchment areas of five CHUs. These were further stratified by age 217 (aged <35 years, and >35 years respectively). Most of the community FGDs were conducted 218 in one sub-county; a government ban on community meetings to control the spread of COVID-219 19 meant that we could not hold FGDs in the second sub-county. FGDs explored community

220 members' perceptions about CRDs, asthma healthcare-seeking practices and experiences with221 asthma management services.

Interviews and FGDs were audio-recorded using digital audio recorders, transferred to laptops the same day of the interview and then transcribed using the denaturalised approach, in the original interview language using MS Word, by research assistants to produce verbatim, transcripts. [40] Transcripts were translated and back-translated from Arabic/Swahili by professional translators and reviewed for meaning. Transcripts were compared with field notes to triangulate data, add supplementary information and enrich the transcripts.

### 228 Data analysis

Initial thematic analysis of the data was undertaken separately in the two countries using the framework approach[41] revealed stigma as an important theme. We then developed a coding framework based on Stangl's 2019 framework.[31] See Fig 1.

232

#### 233 Fig 1. Coding framework development across Kenya and Sudan

234

235 Key domains described in the Stangl framework were applied in the analysis: 1) drivers 236 and facilitators of stigma are those influences that encourage/fuel/shape stigmatising attitudes; 2) an outcome of drivers/ facilitators, 'stigma marking' implies an application of stigma which 237 238 is shaped by personal characteristics such as gender, race, occupation, ethnicity, and kinship; 239 3). consequently, stigma experiences are observed i.e. lived realities and practices based on attitudes such as discrimination, avoidance, verbal abuse and other harms; 4) similarly, self/ 240 241 internalised stigma may occur, i.e. "a stigmatized group member's own adoption of negative 242 societal beliefs and feelings, as well as the social devaluation, associated with their stigmatized

status"[34]; and 5) finally, stigma practices include attitudes, prejudices and behaviours ofother people towards a stigmatised person(s).

Country research teams independently applied the Stangl framework[31] to develop the overarching themes. The final common coding framework was agreed after reviewing transcripts together and resolving any discrepancies. Separate analytical frameworks were developed for health worker interviews, patient interviews and community discussions. Codes were organised into categories and themes for analysis by charting into an Excel spreadsheet. Emerging themes were compared across interview categories.

251

#### 252 Ethical approval

The study was approved by the Research Ethics Committees of Liverpool School of Tropical Medicine (refs18–043; 19-003), the Ministry of Health of Gezira state, Sudan (ref 44/T/KH/1) and the Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (ref SERU No. 3848). We obtained permission from district authorities, including by the county government of Meru (Ref. MRU/MED/MRU/C.50). We obtained written informed consent from all participants. Additional consent was obtained from parents for the adolescent FGD group.

260

261

- 262
- 263
- 264
- 265

# 266 *Participant characteristics*

- 267 Table 2 below summarises the characteristics of the study participants in Kenya and
- 268 Sudan.
- 269 **Table 2**: Summary of Participant Characteristics

	Sudan		Kenya		
Participant group	No and methods	Description	No and methods	Description	
Primary care and hospital clinicians	4 IDI+	2 general practitioners 1 medical director 1 medical assistant 2 males and 2 females with 1-20 years of experience	13 IDI	6 clinical officers 2 medical officers 1 physician; 4 pharmacy staff (5 females and 8 males)	
Community actors	6 FGD	1 adolescent girls group (15-17 years) 1 female group ≥40 years 2 males groups ≥40 years 2 males groups < 40 years	8 FGD, 6 IDI	4 FGDs- community members: - Adult community members >35 years, (1 male, 1 female) -Young community members age 20- 30 years, (1 male, 1 Female) 4 FGD, female CHV 6 IDI, (4 male CHV)	
Male and female asthma patients*	5 IDI~	<ul> <li>4 females</li> <li>1 male</li> <li>Illiterate to university</li> <li>level with age varies</li> <li>from 16-65 years old</li> </ul>	4 IDI	2 adult males >18 years old 2 adult females >18 years old	

<sup>+</sup>Clinicians with 1-20 years of experience

~ Illiterate to university level with age varies from 16-65 years old

# **Results**

272	Asthma is a stigmatised disease in both Sudan and Kenya. Some of the stigma domains of
273	the Stangl framework however showed contextual variations across the two countries. This section
274	highlights areas of convergence as well as divergent perspectives of the research participants
275	across the two countries. Fig 2 shows the key findings with regard to four key domains identified
276	by Stangl et al. (2019)[31]. These domains are inter-related in multiple directions; for example,
277	stigma contributes to poor treatment outcomes, which in turn perpetuate the negative perceptions
278	of people with asthma that shape resistance to diagnosis and manifestations of stigma.
279	
280	Fig 2: Conceptual framework showing key findings
281	
282	Theme 1. Drivers and facilitators
283	Varying perceptions were expressed about the aetiology of asthma. A common perception
284	in both countries was that asthma is hereditary or 'genetic'. People with this view sometimes saw
285	the aetiology as multi-factorial, acknowledging the relevance of other more immediate causes. For
286	example,

287 "We noticed these things many times that there are causing agents, but inheritance plays a very
288 huge role. This is what I put my concentration on." (Male Community FGD, Sudan)

289 Perceiving asthma as hereditary often meant that it was also perceived as incurable.

- 290 "We normally see asthmatic people in the community, and we view it as an inherited disease;
  291 it is there for life". (Male CHVs FGD, Kenya)
- Another common view, particularly in Kenya, but also present in Sudan, was that asthma isinfectious and can be transmitted to others.
- 294 "They do say that if someone for example has asthma and they cough next to you and you
  295 are eating from the same plate, you would also be infected" (Female CHV IDI, Kenya).

The persistent coughing seen by many as a sign of asthma was associated with tuberculosis, which is a stigmatised disease in both countries. In Kenya, symptoms of asthma such as difficulty in breathing were also associated with other stigmatised chronic conditions such as epilepsy as well as sometimes being attributed to witchcraft and/or hereditary.

300 "Some, especially those with little education, view those infected as having been bewitched or
301 are victims of generational curses" (Male CHV IDI, Kenya).

Fear of infection is therefore one of the drivers of both internalised and enacted stigma, which isdiscussed further in manifestations.

304 Negative perceptions commonly expressed about the capacities and social and economic situations 305 of people with asthma highlighted that this is a health condition to fear. In both countries, people 306 with asthma were perceived as 'weak' and unable to contribute economically or socially towards 307 the family or community. For example, in FGDs in Sudan, a male participant commented, "The 308 patient will be transformed from a productive person to a consumer" (Male Community FGD, 309 Sudan), whilst women agreed "He won't be able to work. That will affect him, and then it will 310 affect the society by causing reduction in workers" (Female Community FGD, Sudan). Asthma 311 was perceived as reducing the range of livelihood opportunities open to people. For example,

asthma symptoms were perceived to affect energy to do 'hard' physical work, which might exposethem to dust or changes in temperature.

314 "His opportunities are limited and if he is exposed to hard physical work like dust or air,

315 *coming in and out, from warmth to cold ... that will decrease the patient's job opportunities"* 

- 316 (Male Community FGD, Sudan)
- 317 Educational prospects were perceived to be affected:

318 "My daughter is in high school level. She said there is a girl who gets attacks during school...

319 She would like to study but her health condition will not allow. This will affect her

320 *performance results. It will absolutely affect her work later on.*" (Female Community FGD,

321 Sudan)

In both countries some people also perceived that asthma would affect the sexual performance of sufferers: "*Another thing about asthma, even the other 'work' in bed (sex) is hard*" (Female CHV FGD, Kenya).

325 Some participants added that people with asthma are not able to look after themselves. These 326 perceived limitations to the capacities of people with asthma meant that they were viewed as a 327 social burden.

In Kenya, perceptions of people with asthma as a burden to their families and communities were related to the anticipation they would incur healthcare expenditure, including costs of travel to healthcare facilities during asthma emergencies:

- 331 *"People feel that this asthmatic person... will consume their money. Sometimes people with*
- asthma are rushed to hospital at night, they feel the money they are spending on transporting
- 333 *them to hospital is a burden*" (Female CHV FGD, Kenya).

## 334 Theme 2: Stigma marking

350

Peoples' reactions to a diagnosis of asthma demonstrated stigma 'marking'. In both countries, 335 336 a range of participants described how many people responded by refusing the 'label' of asthma. 337 For example, health workers in Kenva reported: "when you tell them it's asthma they say 'no daktari [doctor]! No! don't write asthma, in 338 339 our family there is nobody who suffers from asthma, that's a bad illness, I don't want to be 340 associated with it'" (Clinical Officer IDI, Kenya). 341 In Sudan, people preferred the term 'allergy' instead of asthma: 342 "Every person here has something making them fear the word "asthma", they call it 343 "hassasya" (allergy) (Male HW, IDI, Sudan) 344 There were mixed opinions about whether stigma marking affected people differently according 345 to socio-economic status. In Kenya, one CHV perceived people with less education were more 346 likely to attribute asthma to generational curses or witchcraft, whilst a healthcare worker emphasised resistance to asthma diagnosis was common regardless of educational background. 347 348 "There is also the stigma attached to diseases like asthma. So, in my experience every time I 349 tell a mum - even one who is educated - that your child could be having asthma, they tell you

A patient in Kenya commented on the greater effect of asthma on people living in poverty due to
 lack of opportunity to avoid triggers:

"No, where did he get it?" (HW IDI, Kenya).

353 *"it affects mostly the poor, do you know that? Because such poor people have to work*354 *whether it is cold or not- and they may get sick, but do not have anyone to support them*355 (Female Patient IDI, Kenya).

## **Theme 3: Stigma manifestations (experiences and practices)**

In both countries, most people with asthma diagnosis and/or symptoms reported hiding these, particularly from their communities. This included making efforts to appear healthy, suppressing their coughs, even when their airways were irritated and carrying on with activities as normal despite feeling unwell. For example,

- 361 *"I don't tell my friend clearly that I am irritated, and moreover; I am not showing that I have*362 *this disease."* (Female Patient, IDI, Sudan)
- In Sudan most interviewees only disclosed symptoms to close family members, such as mothers,
  sisters, wives and brothers. One interviewee had told no one:
- 365 "Not even anyone at home. As they say; the pain is all mine! Who could feel my pain?! They
- *are our wounds, and we tolerate them alone. Hahaha''* (Female Patient, IDI, Sudan)

Such concealment in both contexts related to both anticipated and internalised stigma. Interviewees shared how they wanted to prevent others worrying about them and how they feared no-one would help them, showing concern about being seen differently or discriminated against. They also explained they felt less able to fulfil expected roles in society. For example, one female interviewee in Sudan explained how she felt she was less useful to her family and community than previously: *"I used to work in the fields, but I gave that up ever since I got sick. Now I just stay at home and* 

373 *cook for my kids"* (Female patient, IDI, Sudan)

Another female patient felt less able to contribute to community events: "whenever I go to an *occasion I'll only participate in the conversation, I can't help and serve as I used to.*" (Female
patient, IDI, Sudan)

A male patient similarly expressed that "*I can't do hard work; I can only do desk jobs or easy work...I can't handle exertion*" (Male patient, IDI, Sudan). Many interviewees' narratives suggest they have internalised negative societal perceptions of being a burden to others. In Kenya, some participants felt 'shame' and 'disgrace' leading them to avoid socialising and isolate themselves. As a health worker put it:

382 "some of the patients...pity themselves a lot, and they take it as if they are being burdens to
383 others. So, they stigmatise even themselves" (Social Worker IDI, Kenya).

384 In both countries, interview narratives showed people living with asthma could be discriminated 385 against and socially isolated in their communities. Women in a focus group in Sudan agreed that 386 people would generally avoid someone with a chronic cough for fear of infection: "It is not nice they avoid him/ her .... Everybody worries about himself)" (Female Community, FGD, Sudan), 387 388 whilst men expressed that chronic cough created vulnerability to theft or violence: "He may be get 389 robbed...or anything else. Chest diseases may make patient vulnerable to things like these...he 390 may be tired and not able to defend himself" (Male Community, FGD, Sudan). A CHV in Kenya 391 stated that "People will tend to move away saying you might infect them" (Male CHV IDI, Kenya) 392 and a female patient with asthma concurred: "even neighbours wouldn't serve you a cup of tea, 393 because people fear that you may infect them. They think it is like TB." (Female Patient IDI Kenya)

In addition to fear of infection, in Kenya people with asthma were considered an inconvenience.
Some community members excluded people with asthma from social events for fear that their
illness may disrupt their plans.

397 "Celebrations (laughs). There are those outings that we go to distant places, during the

rainy season, you know, this asthmatic person is isolated or avoided, they won't go with

398

399 them because they might get sick there and bring us complications. So, they are avoided
400 (Female CHV FGD, Kenya)

In both countries, discrimination against individuals with asthma and even their families was
reported with regard to marriage proposals due to perceptions of heredity, which particularly
affected young women in Sudan.

- 404 *"Asthma... will lead to single marital status: It will lower their market value"* (Female
  405 Community, FGD, Sudan).
- 406 "So if people know that that someone has asthma, they don't want their girls to get married
  407 to someone with asthma (Female CHV FGD, Kenya).

In Kenya, CHVs suggested their own lack of knowledge about asthma prior to training meant they
avoided close contact with people with chronic cough, potentially exacerbating community fears:

- 410 "But initially these diseases such as asthma and TB, you know [CHVs] would sometimes
- 411 *talk to [community members] from a distance because they feared contracting the same*
- 412 *diseases. But now we have been trained to know"* (Male CHV IDI, Kenya)
- Enacted stigma within families was less commonly reported. However, one asthma patient inKenya narrated how husband's family had been opposed to their marriage and encouraged him to

415 reject her. Whilst her husband was initially supportive, she described how he later expressed regret416 due to the financial burden of the costs of her treatment:

- 417 So ... these problems caused financial strains and impoverished my husband. ... government 418 hospitals only offered drug prescriptions, but no medicines, so money was never sufficient 419 for other household expenses. We couldn't even afford rent, so we had to move from our 420 rental house to our rural home.....now when we call his parents, they said "we told you to 421 leave this woman alone but you did not listen- this is a problem you have brought on yourself 422 - asthma is not treatable"... It reached a point, I even despised myself...Even my husband... 423 nowadays regrets - he tells me...that if I had disclosed my condition earlier that I am 424 asthmatic, he wouldn't have married me" (Female patient IDI, Kenya). 425 However, in both countries, a minority of community participants did not perceive any enacted
- stigma. For example, in Sudan some men in a focus group perceived that there were no socialconsequences for people with asthma:
- 428 *"I think the social aspect has very tiny effect"* (Male Community, FGD, Sudan).
- Only one patient interviewed in Kenya did not feel that he needed to hide his condition, whilst a
  patient in Sudan did not feel surprise or concern at his diagnosis, *"because it runs in the family."*(Male patient, IDI, Sudan).
- 432 **Theme 4: Outcomes**
- In both countries, people with asthma, community members and healthcare workers agreed
  anticipating and internalising asthma stigma influenced their healthcare seeking behaviour. This
  included not seeking formal healthcare due to fear of a diagnosis. A woman with symptoms of

436 asthma in Sudan explained she had not sought healthcare for her symptoms because she feared a437 diagnosis of asthma and the visibility that using an inhaler would bring:

- 438 *"because I fear they may tell me that I have asthma and I have to use a spray "inhaler"*
- 439 (Female patient, IDI, Sudan)

440 Some people opted for home remedies, buying medicines from pharmacies and/or traditional 441 treatments because of a perception they are suffering from 'allergies.' One patient diagnosed with 442 asthma described how this delayed her initiation of treatment at hospital:

- 443 "My family would say I should go to the doctor, (but) some of them say give her warm
- 444 water, others say sesame oil and some say acacia plant. I would use them for three days,
- 445 staying up the whole time until I feel better, but when I came here to Gezira I started going

446 to hospitals and getting oxygen" (Female patient, IDI, Sudan).

- Women in a focus group explicitly related people hiding their symptoms and not seekinghealthcare due to anticipated stigma:
- 449 "Society's fear of the disease makes TB patients or patient with cough hide their illness
  450 and do not seek medical advice ...so that people will not avoid them" (Female community,
- 451 FGD, Sudan)
- In Kenya, concerns about the costs of care-seeking and the shame associated with asking for helpwere particularly emphasised.
- 454 "Some people will not seek for help until their condition is so bad- they feel ashamed to 455 ask for financial support from other people" (HW IDI, Kenya).
- 456 In both countries, healthcare workers also reported that patients minimise the severity of their457 symptoms to avoid a diagnosis of asthma, in addition to delaying care seeking.

458	People here live in denial. One comes to you and says he has cough for 3 days, while the
459	truth that he has cough for more than a year. '(Male HW, IDI, Sudan)
460	A patient comes in, you try to take her history- you ask, her do you cough? She says 'no'
461	but as you continue the examination, she starts coughing- you ask, "what is that?"
462	(laughter!) (HW IDI, Kenya).
463	Healthcare workers in both countries expressed the challenges they faced with patients accepting
464	a diagnosis of asthma, which contributes towards limited adherence to treatment.
465	"First, the patient must be convinced that s/he has asthma in order to be managed since
466	most of the patients over here are not convinced. They say they have allergy." (Female
467	HW, IDI, Sudan)
468	Resistance to a diagnosis of asthma affected patient willingness to use recommended treatments,
469	including inhalers, oxygen and hospital admissions, and referral. For example, in Sudan, health
470	workers explained some patients even refused to have oxygen when indicated due to a belief that
471	oxygen therapy could convert a temporary allergy into a permanent condition of asthma:
472	'They refuse because they believe that oxygen will make it permanent'. The health worker
473	later continued: If you prescribe an inhaler, the patient will absolutely refuse to take the
474	inhaler" (Female HW, IDI, Sudan).
475	One reason for this was explained in community focus groups where the group discussed concerns
476	about using an inhaler in public making the condition visible. Patients may instead purchase

- 477 antihistamines or corticosteroids from pharmacies as treatment for 'allergies':
- 478 *"I have told you that no one will accept asthma diagnosis... People get accustomed to*479 *purchasing antihistamine; they know what they shall purchase from the pharmacy...*

480 Prednisone is constantly taken. The patient takes prednisone and never takes Ventolin.
481 They call it allergy tablets. I get confused; I thought the patient was taking Antihistamine,
482 and the patient showed me a prednisone strip. They take these tablets. Most patients do
483 that" (Female HW, IDI, Sudan).

484 Communication between health workers and patients can be negatively affected by their different 485 understanding of 'allergy' treatments. Monitoring and evaluation of patients' progress or otherwise 486 can also be negatively affected by patients' reluctance to engage with longer-term management:

487 "However, the answer is always denial of asthma diagnosis and stating it is only allergy,
488 even those cases presenting at the emergency department with attacks at night. We even
489 tried to have a register book for those patients. Unfortunately, the patient leaves before
490 obtaining any information; even we could not get the name of the patient." (Male HW, IDI,
491 Sudan)

In Kenya, health workers reported patients were reluctant to use spacers as well as inhalers, which
particularly affected management of children and presented barriers to demonstration of inhaler use.
Furthermore, open spaces for drug dispensation at the pharmacies in all facilities limit audio privacy,
and appropriate communication of inhaler use. Some healthcare workers observed that patients would
communicate about asthma in hushed tones when receiving medication so as not to be heard.

Health workers in both countries and community health volunteers (CHVs) in Kenya, observed
stigma experiences and practices could exacerbate other co-morbidities, including mental health
problems, diabetes and hypertension. For example, in Kenya CHVs related anticipated social
isolation and anticipated stigma to the development of co-morbidities:

24

501	"Now this person, since he is isolated, you know he develops bad thoughts; he feels that he
502	is a threat to the community, and he can even develop diabetes or hypertension because of
503	that. See now? you have made someone develop a disease they would not have developed"
504	(Female CHV FGD, Kenya).
505	However, CHVs felt their support and explanations could make a difference to stigma and
506	isolation:
507	"If you visit them and let's say the husband or wife has asthma you will see them very
508	depressed. You see them in deep thoughts (and) self-pity. But if you tell them that the disease
509	is just as normal as the others then they feel encouraged such that when you visit the next
510	time she feels jovial" (Female CHV FGD, Kenya).

- In Sudan, health workers reported that patients hiding their illness could lead to deterioration andeven death:
- 513 *"The health condition of some of those patients deteriorated as they hide their illness... They*

514 *hide their illness till they die. Some patients did that*" (Female Community, FGD, Sudan).

515

# 516 **Discussion**

517 Our findings contribute towards a limited literature on understanding stigma associated 518 with asthma in SSA. We found that perceptions about aetiology and prognosis of asthma drive 519 stigma in these contexts; in particular concerns about heritability, incurability and associations 520 with other stigmatised diseases such as TB. People with asthma resist diagnosis as they fear a loss 521 of social status and negative stereotypes, particularly with regard to loss of capacity to fulfil 522 economic and social roles in their families and communities. This stigma marking may affect 523 people differentially according to social position; in particular for young women in Sudan with 524 regard to limiting their opportunities for marriage. Anticipated and internalised stigma are 525 commonly reported by people living with asthma leading them to hide signs, symptoms and 526 diagnosis. People with asthma and community members report enacted stigma, particularly from 527 communities. Anticipated, internalised and enacted stigma all contribute to delayed healthcare 528 seeking and delayed (or limited) uptake of treatment, including self-medication (without 529 appropriate information), incomplete histories given to professionals, inappropriate treatments 530 where 'allergy' medicines are sought, refusing registration for chronic care, and repeated 531 emergency care seeking. Stigma contributes towards challenges for health professionals in 532 communicating diagnosis and managing illness, limiting effective management and contributing 533 towards poor control of symptoms, poor mental health and poor psychosocial well-being.

534 Perceptions of the aetiology and prognosis of asthma are drivers of stigma and occur in a specific 535 socio-economic and health systems context. Health systems in many SSA countries are ill-536 prepared to diagnose and manage asthma (45–48), publicly available accurate information about 537 the disease is limited, and services are financially and geographically inaccessible to many. In this 538 context, high rates of acute exacerbations and death are observed, leading communities to conclude 539 people living with asthma will die young and perpetuating fear of the condition. This sets up a 540 vicious cycle of people living with uncontrolled symptoms that are visible in communities, 541 exacerbating stigma and decreasing uptake of services (Fig 3).

### 542 Fig 3: The interplay of uncontrolled asthma management and stigma

543

544 Health-related stigma results from perceptions of threat in contexts of low-income and insecure 545 livelihoods. Where livelihoods depend on physical labour, reduced capacities due to uncontrolled 546 asthma are a threat to family economic security; educational prospects may also be affected, 547 limiting future employment opportunities. Concerns about economic and social threats to 548 individuals and families, may therefore be understood as 'situated rationality'(49). Thus, our 549 research contributes to a deepening understanding of how asthma stigma is a social and structural 550 process, rather than purely an interpersonal phenomenon. There were few examples of intersecting 551 stigma at the individual level, although the study was not designed to explore these. However, 552 some participants commented people living in poverty are most vulnerable to the effects of asthma, 553 and the anticipated costs of accessing care are perceived as a threat in a low-income context, further 554 driving stigma.

### 555 *Perceptions of aetiology in health systems context*

556 Perceptions of asthma aetiology identified in the study are partially in line with existing 557 biomedical understandings. For example, perceptions of asthma as heritable are in line with 558 evidence that around 50% of people with asthma have a family history of the disease. However, a 559 potential consequence of perceived heritability is that people with no known family history may 560 not recognise the possibility that they have the condition. Whilst sometimes the perception of 561 asthma as common within a family seems to support its acceptance, perceptions of heritability 562 have differential consequences for young people, and especially women, in patriarchal societal 563 contexts where marriage and childbearing are central to women's social and economic 564 security[42]. Respiratory symptoms being equated with tuberculosis may result from widespread 565 education on signs and symptoms by TB control programmes in SSA. As we have reported 566 elsewhere, such programs rarely provide further diagnosis or care to individuals who test negative

567 for tuberculosis[37,43]. Associations with TB lead to misplaced concerns about risks of infection 568 from associating with symptomatic individuals. The conflation of asthma and 'allergies' is further 569 in line with evidence of the role of atopy in asthma aetiology for some; in the Global North, about 570 50-60% of asthma in children has an allergic/atopic aetiology[44]. The term 'allergies' also 571 appears to function as a label for symptoms that avoids the stigma marking associated with the 572 diagnostic label of asthma. However, this has problematic consequences for treatment. Our study 573 found that antihistamines and oral corticosteroids e.g prednisolone were commonly used to treat 574 symptoms which is consistent with a previous study [45]; these are not indicated in asthma 575 guidelines, and therefore risk wasting limited resources, causing side effects and further 576 compounding perceptions that asthma cannot be effectively managed.

### 577 Addressing stigma through demand and supply side approaches

578 Efforts to address gaps in asthma care in LMICs have focused on ensuring 'supply side' 579 factors such as releasing new policy and guidelines, improving access to peak flow meters and 580 drugs and training health care workers. Whilst these efforts are critically important to address the 581 wider context facilitating stigma, our findings show engagement with the 'demand side' is 582 important in determining how and when health services are accessed. In practice, demand and 583 supply are interconnected and a holistic perspective is required, or uptake will continue to be poor 584 as perceived threats to the individual outweigh the benefits of health seeking. Demand and supply 585 particularly interact in clinical encounters between healthcare workers and patients, where 586 anticipated stigma affects accurate history taking, poor explanation and negative patient responses 587 (resistance) to asthma diagnosis. Addressing this challenge requires nuanced communication by 588 health professionals in ways that engage with patients' perspectives and socio-economic realities 589 as well as the biomedical evidence base. For example, it may be helpful to explain that whilst asthma may be inherited, this is not always the case and heritability need not be feared, since asthma is controllable with relatively low-cost medication. Similarly, the allergy label may potentially be useful if it provides patients with a way to access and use appropriate treatment, usually inhaled corticosteroids, and they are informed that antihistamines are ineffective.

594 Learning from other stigmatised conditions reveals possible strategies. Experience with HIV 595 diagnosis and treatment in SSA shows affordable access to medication, counselling and 596 confidentiality contribute to stigma reduction, particularly because this results in adherence to anti-597 retroviral medication[46], which observably reduces or eliminates disease symptoms, such as 598 weight loss, and prevents death. Such successful treatment programs can lead to social diffusion 599 of knowledge of these positive outcomes, where visible improvements in the health of people 600 living with HIV challenge negative stereotypes and encourage others to seek testing and treatment, 601 breaking the vicious cycle seen in Fig 3. However, this has been achieved with substantial 602 investments through vertical disease control programmes.

603 Tuberculosis (TB) control programs may similarly offer valuable insights for managing asthma in 604 primary care settings due to the importance of medication adherence. Community Health Workers 605 (CHWs) have played a vital role in TB programs by providing directly observed therapy (DOT) 606 and building trust with patients.[47] Whilst training of health workers on both technical aspects of 607 diagnosis and treatment and communication is important, limitations on time for patient 608 consultation and privacy are likely barriers to this approach for asthma in general health services. 609 The potential role of primary care and CHWs in asthma management requires careful 610 consideration, taking into account the differences between the two conditions. Asthma does not 611 require DOT, but ensuring long-term medication adherence remains crucial. Primary care 612 physicians can leverage their existing patient relationships for personalised asthma management 613 plans. CHWs, with their deep community connections, may focus on education, adherence support, 614 and reducing stigma within communities. Public communication of this nuanced information will 615 also be important to support changed perceptions among family and community members. 616 Educational campaigns, including by celebrity champions can address misconceptions about 617 asthma, highlight the benefits of treatment, and encourage open communication between patients 618 and healthcare providers. By fostering understanding within families and communities, social 619 diffusion of positive treatment outcomes can be harnessed to reduce stigma and encourage timely 620 diagnosis and management of asthma.

621 Recent developments in asthma treatments such as the emphasis on the 'as needed' use of 622 combined rapid onset inhaled long-acting beta-agonists with inhaled corticosteroids[48] are likely 623 to support stigma reduction as treatment works with patients' relief-seeking behaviour (due to the 624 fast-acting property of formoterol for symptom relief) [49] to improve symptoms. Moreover, the 625 prolonged duration of action of these inhaler preparations will also reduce the need for affected 626 people to use an inhaler in public (as was the case for older short acting beta agonist preparations). 627 The use of inhaled corticosteroids at much lower doses than oral corticosteroids is associated with 628 far fewer side effects. Effective communication of this, and of the fast-acting properties of 629 formoterol for symptom relief may also contribute to promoting adherence and reducing stigma. 630 The Asthma Drug Facility initiative [14] found that where individuals with asthma who, despite 631 the stigma, were able to adhere to use of inhalers and attend follow-up, these patients had 632 controlled asthma, and drastic reductions in asthma related emergency visits and hospital 633 admissions.

634

635

### 636 Applying a stigma framework

637 Stangl's framework worked well for asthma stigma with regard to the relevance of 638 distinguishing between drivers of stigma (particularly with regard to fear of the illness and its 639 consequences for affected people), stigma marking (which in this case relates particularly to 640 diagnosis and its communication), stigma experiences, and consequences (for people affected and 641 for healthcare providers). We found it helpful to further distinguish stigma experiences and practices. for example between perceived, enacted and internalised experiences, since all were 642 643 reported within our data and may have different implications for action. In particular, our 644 application of the framework enables holistic consideration of stigma as a socio-economically 645 produced rather than individual interpersonal phenomenon, which therefore requires actions across 646 its dimensions by a range of actors at multiple socio-ecological levels, including policy, institutional and community. 647

## 648 **Limitations**:

649 The COVID-19 pandemic unfortunately hindered our ability to conduct all planned FGDs
650 in Sudan. This might have limited our ability to achieve saturation, the point at which no new
651 significant information emerges from further data collection.

Moreover, since this was primarily a qualitative study focused on health systems, we did not collect data on the specific processes of asthma diagnosis or inhaler use by patients. This limits our ability to analyse opinions or comments regarding treatment outcomes, healthcare service utilisation related to asthma, or the patient experience with these aspects of their care.

656 Since the study focused on adults, we were not able to fully explore the experiences of children.

657 In addition, while stigma was not the original focus of the study, a comprehensive set of data

658 emerged on this theme. However, due to the study design and focus on health systems, we may659 not have been able to fully explore the nuances of stigma associated with asthma.

660

# 661 Conclusion

662 The underdiagnosis and undertreatment of asthma in the Global South is a human rights 663 violation, since people with asthma continue to suffer and die despite availability of safe, highly 664 clinically and cost-effective inhaled treatments widely used in the Global North. Our findings 665 suggest action is required at multiple levels across the process of stigma production to create 666 conditions that maximise the possibilities for patients to seek care, accept a diagnosis and adhere 667 to highly effective inhaled medication and follow-up with the support of their families and 668 communities. This approach offers the potential to intervene in the cycle of poor asthma 669 management and stigma (Fig 3) and create instead a virtuous cycle in which experiences and 670 observations of accessible, effective treatment significantly reduce the threat associated with the 671 label of asthma.

# 672 Acknowledgments

We acknowledge the county government of Meru, healthcare workers and community members for supporting this research; and the research team members: Damian Mwaura, Noel Chemwa, Ruth Akiso, Elizabeth Sitati for supporting data collection in Kenya. We would also like to express our gratitude for the support received from the Ministry of Health in Gezira State, the health workers at both the Epilab and Non-Epilab sites, the patients, the members of the community, and the research team, including Ms. Hana A.Elsadig, Dr. Bandar Noory, Hind 679 Eltigani, Sayed Gamal, Sahar Aladdin, and Ayaa Abddin. Their assistance was invaluable in 680 conducting research activities and collecting data in Sudan. We thank the NIHR Global Health Research Unit on Lung Health and TB in Africa at LSTM "IMPALA" for helping to make this 681 682 work possible. In relation to IMPALA (grant number 16/136/35) specifically: IMPALA was 683 commissioned by the National Institute of Health Research using Official Development Assistance 684 (ODA) funding. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of 685 686 Health".

687

# 688 **References**

689

690

1.

691 369 diseases and injuries in 204 countries and territories, 1990–2019; a systematic 692 analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396: 1204–1222. 693 doi:10.1016/S0140-6736(20)30925-9 694 2. Thomsen SF. Genetics of asthma: an introduction for the clinician. Eur Clin Respir J. 695 2015;2: 24643. doi:10.3402/ecrj.v2.24643 696 3. Ahmed R, Robinson R, Mortimer K. The epidemiology of noncommunicable respiratory 697 disease in sub-Saharan Africa, the Middle East, and North Africa. Malawi Medical 698 Journal. 2017;29: 203. doi:10.4314/mmj.v29i2.24 699 Asher MI, Rutter CE, Bissell K, Chiang C-Y, El Sony A, Ellwood E, et al. Worldwide 4. 700 trends in the burden of asthma symptoms in school-aged children: Global Asthma 701 Network Phase I cross-sectional study. The Lancet. 2021;398: 1569–1580. 702 doi:10.1016/S0140-6736(21)01450-1 703 5. Adeloye D, Chan KY, Rudan I, Campbell H. An estimate of asthma prevalence in Africa: 704 a systematic analysis. Croat Med J. 2013;54: 519–531. doi:10.3325/cmj.2013.54.519 705 Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the 6. 706 prevalence and severity of asthma symptoms: Phase Three of the International Study of 707 Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64: 476–483. 708 doi:10.1136/thx.2008.106609 709 7. Ait-Khaled N, Odhiambo J, Pearce N, Adjoh KS, Maesano IA, Benhabyles B, et al. 710 Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International Study of Asthma and Allergies in Childhood Phase III. Allergy. 711 712 2007;62: 247–258. doi:10.1111/j.1398-9995.2007.01325.x WHO. Global surveillance, prevention and control of chronic respiratory diseases: a 713 8. 714 comprehensive approach. 2007 [cited 6 Jun 2024]. Available: 715 https://www.who.int/publications/i/item/global-surveillance-prevention-and-control-of-716 chronic-respiratory-diseases 9. 717 Haakenstad A, Coates M, Marx A, Bukhman G, Verguet S. Disaggregating catastrophic 718 health expenditure by disease area: Cross-country estimates based on the World Health 719 Surveys. BMC Med. 2019;17: 1-9. doi:10.1186/s12916-019-1266-0 720 10. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 721 2022. Available: https://ginasthma.org/gina-reports/ 722 Aït-khaled N, Enarson DA. Chronic air fl ow limitation in developing countries : burden 11. 723 and priorities. International Journal of COPD. 2007;2: 141–150. 724 Royal College of Physicians. Why Asthma Still Kills: the National Review of Asthma 12. 725 Deaths (NRAD) Confidential Enquiry Report. London; 2014. Available: 726 https://www.rcp.ac.uk/media/i2jjkbmc/why-asthma-still-kills-full-report.pdf 727 El Sony AI, Chiang C-Y, Malik E, Hassanain SA, Hussien H, Khamis AH, et al. Standard 13. case management of asthma in Sudan: a pilot project. Public Health Action. 2013;3: 247-728 729 252. doi:10.5588/pha.13.0019

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of

- Chiang C-Y, Bissell K, Macé C, Perrin C, Marks G, Mortimer K, et al. The Asthma Drug
  Facility and the future management of asthma. The International Journal of Tuberculosis
  and Lung Disease. 2022;26: 388–391. doi:10.5588/ijtld.22.0034
- Rockers PC, Laing RO, Ashigbie PG, Onyango MA, Mukiira CK, Wirtz VJ. Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial. Lancet Glob Health. 2019;7: e492–e502. doi:10.1016/S2214-109X(18)30563-1
- Ahmad S, Ismail NE. Stigma in the lives of asthma patients: A review from the literature.
  Int J Pharm Pharm Sci. 2015;7: 40–46.
- 739 17. Rose S, Paul C, Boyes A, Kelly B, Roach D. Stigma-related experiences in non740 communicable respiratory diseases: A systematic review. Chron Respir Dis. 2017;14:
  741 199–216. doi:10.1177/1479972316680847
- 742 18. SNADDEN D, BROWN JB. Asthma and Stigma. Fam Pract. 1991;8: 329–335.
   743 doi:10.1093/fampra/8.4.329
- Monaghan LF, Gabe J. Managing Stigma: Young People, Asthma, and the Politics of
  Chronic Illness. Qual Health Res. 2019;29: 1877–1889. doi:10.1177/1049732318808521
- De Simoni A, Horne R, Fleming L, Bush A, Griffiths C. What do adolescents with asthma
  really think about adherence to inhalers? Insights from a qualitative analysis of a UK
  online forum. BMJ Open. 2017;7: 1–12. doi:10.1136/bmjopen-2016-015245
- Ahmad S, Ismail NE. Stigma in the lives of asthma patients: A review from the literature.
  International Journal of Pharmacy and Pharmaceutical Sciences. 2015. pp. 40–46.
- Shimwela M, Mwita JC, Mwandri M, Rwegerera GM, Mashalla Y, Mugusi F. Asthma
  prevalence, knowledge, and perceptions among secondary school pupils in rural and urban
  coastal districts in Tanzania. BMC Public Health. 2014;14: 387. doi:10.1186/1471-245814-387
- Egere U, Shayo EH, Chinouya M, Taegtmeyer M, Ardrey J, Mpagama S, et al. "Honestly,
  this problem has affected me a lot": a qualitative exploration of the lived experiences of
  people with chronic respiratory disease in Sudan and Tanzania. BMC Public Health.
  2023;23: 1–13. doi:10.1186/s12889-023-15368-6
- van Gemert F, Chavannes N, Nabadda N, Luzige S, Kirenga B, Eggermont C, et al.
  Impact of chronic respiratory symptoms in a rural area of sub-Saharan Africa: An in-depth qualitative study in the Masindi district of Uganda. Primary Care Respiratory Journal.
  2013;22: 300–305. doi:10.4104/pcrj.2013.00064
- Simba JM, Marete I, Waihenya R, Kombe Y, Mwangi A, Kithuci RK, et al. Asthma
  control and factors associated with control among children attending clinics at a national
  referral hospital in western Kenya. East Afr Med J. 2018;95: 1844–1851.
- Zaraket R, Al-Tannir MA, Bin Abdulhak AA, Shatila A, Lababidi H. Parental perceptions
  and beliefs about childhood asthma: a cross-sectional study. Croat Med J. 2011;52: 637–
  643. doi:10.3325/cmj.2011.52.637
- 769 27. Goffman E. Stigma: Notes on the Management of Spoiled Identity. New York: Simon &
  770 Schuster, Inc.; 1963.
- 771 28. Jones EE. Social stigma: The psychology of marked relationships. (No Title). 1984.
- 29. Link BG, Phelan JC. Conceptualizing Stigma. Annu Rev Sociol. 2001;27: 363–385.
  doi:10.1146/annurev.soc.27.1.363
- Parker R, Aggleton P. HIV- and AIDS-related stigma and discrimination: A conceptual
   framework and implications for action. 1st ed. Culture, Society and Sexuality. 1st ed.

776 Routledge; 2006. p. 16. Available: 777 https://www.taylorfrancis.com/chapters/edit/10.4324/9780203966105-42/hiv-aids-related-778 stigma-discrimination-conceptual-framework-implications-action-richard-parker-peter-779 aggleton 780 Stangl AL, Earnshaw VA, Logie CH, van Brakel W, C. Simbayi L, Barré I, et al. The 31. 781 Health Stigma and Discrimination Framework: a global, crosscutting framework to inform 782 research, intervention development, and policy on health-related stigmas. BMC Med. 783 2019;17: 31. doi:10.1186/s12916-019-1271-3 784 32. Farmer P. On Suffering and Structural Violence: A View from Below. Daedalus. 785 1996;125: 261–283. Available: http://www.jstor.org/stable/20027362 Gandy M, Zumla A. The resurgence of disease: social and historical perspectives on the 786 33. 787 'new' tuberculosis. Soc Sci Med. 2002;55: 385-396. doi:https://doi.org/10.1016/S0277-788 9536(01)00176-9 789 Rao D, Desmond M, Andrasik M, Rasberry T, Lambert N, Cohn SE, et al. Feasibility, 34. 790 Acceptability, and Preliminary Efficacy of the Unity Workshop: An Internalized Stigma 791 Reduction Intervention for African American Women Living with HIV. AIDS Patient 792 Care STDS. 2012;26: 614-620. doi:10.1089/apc.2012.0106 793 35. Steward WT, Herek GM, Ramakrishna J, Bharat S, Chandy S, Wrubel J, et al. HIV-794 related stigma: Adapting a theoretical framework for use in India. Soc Sci Med. 2008;67: 795 1225-1235. doi:https://doi.org/10.1016/j.socscimed.2008.05.032 796 36. Scambler G. Stigma and disease: changing paradigms. The Lancet. 1998;352: 1054–1055. 797 doi:10.1016/S0140-6736(98)08068-4 798 37. Mulupi S, Ayakaka I, Tolhurst R, Kozak N, Shayo EH, Abdalla E, et al. What are the 799 barriers to the diagnosis and management of chronic respiratory disease in sub-Saharan 800 Africa? A qualitative study with healthcare workers, national and regional policy 801 stakeholders in five countries. BMJ Open. 2022;12. doi:10.1136/bmjopen-2021-052105 LSTM. The International Multidisciplinary Programme to Address Lung Health and TB in 802 38. 803 Africa "IMPALA." [cited 24 Apr 2024]. Available: https://www.lstmed.ac.uk/impala 804 39. Epilab. The Epidemiological Laboratory for Research and Development. [cited 24 Apr 805 2024]. Available: http://epilab-sd.org 806 Nascimento L da S, Steinbruch FK. "The interviews were transcribed", but how? 40. 807 Reflections on management research. RAUSP Management Journal. 2019;54: 413-429. 808 41. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for 809 the analysis of qualitative data in multi-disciplinary health research. BMC Med Res 810 Methodol. 2013;13: 117. doi:10.1186/1471-2288-13-117 811 Dean L, Obasi A, El Sony A, Fadul S, El Hassan H, Thomson R, et al. "He is suitable for 42. her, of course he is our relative": a qualitative exploration of the drivers and implications 812 813 of child marriage in Gezira State, Sudan. BMJ Glob Health. 2019;4: e001264. 814 43. Egere U, Shayo E, Ntinginya N, Osman R, Noory B, Mpagama S, et al. Management of 815 chronic lung diseases in Sudan and Tanzania: how ready are the country health systems? 816 BMC Health Serv Res. 2021;21: 734. doi:10.1186/s12913-021-06759-9 817 44. Comberiati P, Di Cicco ME, D'Elios S, Peroni DG. How much asthma is atopic in 818 children? Frontiers in Pediatrics. Frontiers Media S.A.; 2017. 819 doi:10.3389/fped.2017.00122 820 45. Osman R, Ahmed K, ElSony A. Factors associated with uncontrolled asthma among Sudanese adult patients. Journal of the Pan African Thoracic Society. 2021;2: 85–93. 821

822	46.	Haberer JE, Sabin L, Amico KR, Orrell C, Galárraga O, Tsai AC, et al. Improving
823		antiretroviral therapy adherence in resource-limited settings at scale: a discussion of
824		interventions and recommendations. African Journal of Reproduction and Gynaecological
825		Endoscopy. 2017;20.
826	47.	Zhang H, Ehiri J, Yang H, Tang S, Li Y. Impact of Community-Based DOT on
827		Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. PLoS One.
000		

- 828 2016;11: e0147744-. Available: https://doi.org/10.1371/journal.pone.0147744
- 829 48. Global Initiative for Asthma. Global strategy for asthma management and prevention.
  830 2020.
- 49. McIvor A, Kaplan A. A call to action for improving clinical outcomes in patients with
  asthma. NPJ Prim Care Respir Med. 2020;30: 1–5. doi:10.1038/s41533-020-00211-x
- 833




Fig1 Coding framework development across Kenya and Sudan




Fig2 Conceptual framework showing key findings




Fig3 The interplay of uncontrolled asthma management and stig